Z Gastroenterol 2015; 53 - KG151
DOI: 10.1055/s-0035-1559177

Gender- and age-related co-morbidities of patients undergoing treatment of chronic HCV G1 infection in German real-life

P Buggisch 1, H Löhr 2, G Teuber 2, H Steffens 3, M Kraus 4, C John 3, P Geyer 2, B Weber 5, T Witthöft 2, A Herrmann 6, M Hoesl 2, U Naumann 7, E Zehnter 2, D Hartmann 8, B Dreher 8, M Bilzer 8
  • 1ifi Institut für interdisziplinäre Medizin, Hamburg, Deutschland
  • 2Gastroenterological Practice, Wiesbaden, Deutschland
  • 3Practice of Internal Medicine, Berlin, Deutschland
  • 4Klinikum Burghausen, Department II, Burghausen, Deutschland
  • 5Competence Center Addiction, Kassel, Deutschland
  • 6Friedrich-Schiller-University, Jena, Deutschland
  • 7Praxiszentrum Kaiserdamm, Berlin, Deutschland
  • 8MSD Sharp & Dohme GmbH, Haar, Deutschland

Background: Information about co-morbidities of patients (pts) currently treated for chronic HCV genotype 1 (G1) infection in real-life is scarce. The present interim analysis of the NOVUS observational study was therefore aimed to investigate the frequency of ongoing co-morbidities of pts with chronic HCV G1 infection in German real-life according to gender and age.

Methods: From April 2012 until January 2014, 536 pts with HCV G1 infection were recruited in the ongoing NOVUS study by 97 practices and hospitals in Germany. Until now, pre-existing co-morbidities before triple therapy of HCV G1 infection with boceprevir were documented for 469 pts (treatment-naïve N = 306, pretreated N = 154).

Results: 599 and ongoing co-morbidities were reported for 469 pts before treatment of HCV G1 infection (multiple answers allowed). The most frequently reported co-morbidities were obesity (BMI > 30 kg/m2) (19%), cardiovascular diseases (18%), psychiatric disorders (14%), opiate substitution (13%), gastrointestinal diseases (11%), metabolic disorders (8%), thyroid gland diseases (7%), bone and joint diseases (6%), skin diseases (5%), HIV-co-infection (4%) and kidney diseases (2%). When co-morbidities were analyzed by gender (female vs. male), thyroid diseases occurred more frequently in females (13% vs. 3%, P 50 years), cardiovascular 9% vs. 28%, P < 0.0001), while opiate substitution (9% vs. 15%, P < 0.04) and HIV-co-infection (1% vs. 6%, P < 0.01) occurred less frequently in female pts. Regarding age (50 years), cardiovascular 9% vs. 28%, P < 0.0001), thyroid (3% vs. 12%, P = 0.0002) and kidney diseases (0.4% vs. 5%, P = 0.0025) were more frequently reported in pts elder than 50 years, while opiate dependence (20% vs. 4%, P < 0.0001) and HIV-co-infections (6% vs. 1%) were less frequently reported in elder pts. In contrast, obesity, psychiatric disorders and diseases of skin and bone/joints showed no association with gender and age.

Conclusions: The present analysis demonstrates that co-morbidities are a frequent problem in pts undergoing treatment of HCV G1 infection in real-life and that several co-morbidities are related to gender or age.